Savolitinib NDA accepted by the NMPA with Priority Review status and Breakthrough Therapy designation for 2L EGFRm NSCLC patients with MET amplification, in combination with TAGRISSO ® (osimertinib), ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The drug is the only approved oral SYK inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Against this backdrop, investors have an opportunity to invest in stable robotics stocks, Stryker Corporation (SYK), Fanuc Corporation (FANUY), and UiPath Inc. (PATH), which are at the forefront of ...

Immune thrombocytopenia (ITP) is an autoimmune disease, characterized by increased bleeding due to a reduced platelet count. The pathogenesis of ITP is very complex and involves autoantibody ...

Stryker Corporation’s SYK shares closed the trading session at $385.18 on Friday, 5.2% below its 52-week high of $406.19 reached on Jan. 28, 2025. In the past six months, SYK has gained 13%.

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our P/B Growth Investor model based on the published strategy of ...